BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
Key takeaways
- Bio NTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM Market Beat Fri, May 15, 2026 at 11:10 PM GMT+7 7 min read BMY BNTX PFE Key Points Interested in Bio NTech SE Sponsored ADR?
- Bio NTech is shifting deeper into oncology, with management highlighting more than 25 Phase 2/3 studies, 17 clinical programs and several 2026 data readouts expected.
- The company announced a share repurchase program of up to $1 billion over the next 12 months, citing confidence in its science and capital position.
Bio NTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM Market Beat Fri, May 15, 2026 at 11:10 PM GMT+7 7 min read BMY BNTX PFE Key Points Interested in Bio NTech SE Sponsored ADR? Here are five stocks we like better.
Bio NTech is shifting deeper into oncology, with management highlighting more than 25 Phase 2/3 studies, 17 clinical programs and several 2026 data readouts expected. The company also pointed to pumitamig as its flagship asset and its new global collaboration with Bristol Myers Squibb.
The company announced a share repurchase program of up to $1 billion over the next 12 months, citing confidence in its science and capital position. BioNTech ended 2025 with EUR 17.2 billion in cash and marketable securities and reaffirmed 2026 revenue and expense guidance.